Table 2.
In-vitro characterization and evaluation tests of the physicochemical properties of some compounds in PEGylated liposomes.
|
Types of cancer cells |
Substances | Methods of preparation | Types of PEGylated liposomes | Effects | References |
|---|---|---|---|---|---|
| Human liver hepatocellular carcinoma cell line (HepG2) | Goniodiol | Thin-film hydration method | Goniodiol-loaded PEGylated liposome (PEG-A-DSPE and PEG-P-DSPE) | The amount of goniodiol in PEGylated liposomes was greater than in regular liposomes. | [36] |
| NT8e oral cancer cell line | 5-Fluorouracil (5 FU) and Resveratrol (RES) | Thin-film hydration method | PEGylated dual liposomal formulation | Improved the cytotoxicity in comparison with the free drug | [32] |
| B16F1 melanoma | Plumbagin (PLB) | Thin-film hydration method | PLB liposomes (PLB Plumbagin) | Enhanced plasma half-life and therapeutic efficacy | [23] |
| Breast cancer cell line (MCF-7 and T47D) | Anethole [1-methoxy-4-(1-propenyl) benzene] derived from Foeniculum vulgare Mill— | Reverse phase evaporation technique | PEGylated liposomal trans-anethole | Toxicological studies of MCF-7 and T47D cell lines revealed 9- and 8-fold cytotoxicity effects, respectively, when compared to free drugs. | [31] |
| Breast cancer (MCF-7) | Paclitaxel (PCX) | Film dispersion-extrusion-ammonium sulfate gradient method | PEGylated nanoliposomes, nano-archaeosome, nanoliposomes | Increment in IC50 values: PEGylated nanoliposomes < Nanoliposomes < Nano-archaeosomes |
[39] |
| The human breast cancer cell lines SK-BR-3, BT-474 and MDA-MB-231 | Paclitaxel and Herceptin (a recombinant humanized monoclonal antibody) | Thin-film hydration method | Paclitaxel-Loaded PEGylated Immunoliposomes | Different activities in: Paclitaxel-Loaded PEGylated Immunoliposomes (PIL) Paclitaxel-Loaded PEGylated liposomes (PL) Paclitaxel-Loaded PEGylated Immunoliposomes (PIL) + Herceptin |
[60] |
| C26 murine colon carcinoma solid tumor model | Rhenium-188 | Ready-made PEGylated liposome (Nano-X) | Rhenium-188 in PEGylated nanoliposomes | Increased apoptotic nuclei in188Re-liposome-treated mice. | [41] |
| Breast cancer cells (MCF-7) | Resveratrol, Paclitaxel |
Thin-film hydration method | PEGylated liposomes containing Res and/or PTX | The Res liposomes had minimal cytotoxicity, but the PTX liposomes and the composite liposomes indicated cytotoxicity. The cytotoxicity of composite liposomes containing PTX and a greater dosage of Res was the highest. |
[62] |
| SW620 PC-3 MDA-MB-231 A549 U251 U87 HepG2 cell lines |
Bufalin | Thin-film evaporation method and high-pressure homogenization method | Bufalin-loaded PEGylated liposomes and Bufalin-loaded liposomes | The cytotoxicity of blank liposomes was determined to be within acceptable limits, but bufalin-loaded PEGylated liposomes were shown to be more hazardous to U251 cells than the bufalin entity. U251 and U87 glioma cancer cells were more susceptible to bufalin than the other cancer cells examined. |
[50] |
| KunMing Mice: Mice ascites tumor H-22 Cells |
Copper Oleate liposome Cu(OI)2-L and Disulfiram (DSF) | Alcohol injection method | Copper Oleate Liposome (Cu(OI)2-L) DTC diethyldithiocarbamate |
Enhanced tumor inhibition rate with the treatment of Cu(OI)2-L and DSF nanoparticles indicating an improved synergistic antitumor effect. | [63] |
| HT29 colon cancer cells and HEK293T Human embryonic kidney |
Curcumin (CUR) and Aptamers (APT) | Nanoprecipitation technique with a slight modification. | Encapsulated CUR (curcumin) with PLGA-lecithin-PEG nanoparticles (CUR-NPs) |
– | [70] |
| Mice xenograft | Gemcitabine (GEM) | Film dispersion-extrusion-ammonium sulfate gradient method | Lipoid S-100, Cholesterol and DSPE-PEG2000 (at a molar ratio of 9:2:0.07) | Intravenous administration showed tumor inhibition rate of GEM-Lip was 6.25-fold as that of GEM-Solution | [71] Scholar |
| In vitro A172 human and C6 rat glioma cell lines | Carboplatin | Reverse-phase evaporation technique | Lecithin, cholesterol, polyethylene glycol 4000, DSPE-mPEG-2000 | Enhanced cyto- toxicity compared with free drug | [72] |
| The H630WT (passage 13–27) and H630R10 (passage 4–16) cells | Disulfiram | ethanol-based proliposome methods (80–90 nm) | Hydrogenated soya phosphatidylcholine (HSPC) or dipalmitoyl phosphatidylcholine (DPPC) and N-(Carbonyl-methoxypolyethylenglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-PEG2000) with cholesterol | Improved stability of disulfiram in serum | [73] |
| Glioma C6 cells | Doxorubicin and carboplatin | Reverse phase evaporation methods | lecithin, cholesterol, DOX/CB, and DSPE-PEG2000 | PEG-Lip-DOX/CB significantly increased the effect of loaded drugs in cytotoxicity by 1.5-fold | [74] |